vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and TIC Solutions, Inc. (TIC). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $508.3M, roughly 1.2× TIC Solutions, Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -9.3%, a 50.1% gap on every dollar of revenue. EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $37.1M).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
EXEL vs TIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $508.3M |
| Net Profit | $244.5M | $-47.2M |
| Gross Margin | 95.6% | 35.2% |
| Operating Margin | 39.3% | -3.8% |
| Net Margin | 40.8% | -9.3% |
| Revenue YoY | 5.6% | — |
| Net Profit YoY | 74.8% | — |
| EPS (diluted) | $0.89 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $508.3M | ||
| Q3 25 | $568.3M | $473.9M | ||
| Q2 25 | $555.4M | $313.9M | ||
| Q1 25 | $566.8M | $234.2M | ||
| Q3 24 | $539.5M | — | ||
| Q2 24 | $637.2M | — | ||
| Q1 24 | $425.2M | — |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $-47.2M | ||
| Q3 25 | $184.8M | $-13.9M | ||
| Q2 25 | $159.6M | $-233.0K | ||
| Q1 25 | $139.9M | $-25.8M | ||
| Q3 24 | $118.0M | — | ||
| Q2 24 | $226.1M | — | ||
| Q1 24 | $37.3M | — |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 35.2% | ||
| Q3 25 | 96.6% | 32.2% | ||
| Q2 25 | 96.5% | 23.6% | ||
| Q1 25 | 96.5% | 18.6% | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — | ||
| Q1 24 | 95.0% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | -3.8% | ||
| Q3 25 | 37.6% | -1.4% | ||
| Q2 25 | 33.6% | 5.8% | ||
| Q1 25 | 28.8% | -4.0% | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 43.3% | — | ||
| Q1 24 | 6.9% | — |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | -9.3% | ||
| Q3 25 | 32.5% | -2.9% | ||
| Q2 25 | 28.7% | -0.1% | ||
| Q1 25 | 24.7% | -11.0% | ||
| Q3 24 | 21.9% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 8.8% | — |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | — | ||
| Q3 25 | $0.65 | $-0.08 | ||
| Q2 25 | $0.55 | — | ||
| Q1 25 | $0.47 | — | ||
| Q3 24 | $0.40 | — | ||
| Q2 24 | $0.77 | — | ||
| Q1 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $439.5M |
| Total DebtLower is stronger | — | $1.6B |
| Stockholders' EquityBook value | $2.2B | $2.2B |
| Total Assets | $2.8B | $4.4B |
| Debt / EquityLower = less leverage | — | 0.74× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $439.5M | ||
| Q3 25 | $791.1M | $164.4M | ||
| Q2 25 | $1.0B | $130.1M | ||
| Q1 25 | $1.1B | $155.7M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $963.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $751.3M | ||
| Q1 25 | — | $752.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.2B | ||
| Q3 25 | $2.0B | $2.0B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.2B | $1.1B | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $4.4B | ||
| Q3 25 | $2.7B | $4.2B | ||
| Q2 25 | $2.8B | $2.2B | ||
| Q1 25 | $2.9B | $2.2B | ||
| Q3 24 | $3.0B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.8B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.74× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 0.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $49.7M |
| Free Cash FlowOCF − Capex | $332.4M | $37.1M |
| FCF MarginFCF / Revenue | 55.5% | 7.3% |
| Capex IntensityCapex / Revenue | 0.2% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $61.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $49.7M | ||
| Q3 25 | $49.0M | $19.0M | ||
| Q2 25 | $211.4M | $-6.5M | ||
| Q1 25 | $240.3M | $32.8M | ||
| Q3 24 | $271.3M | — | ||
| Q2 24 | $119.5M | — | ||
| Q1 24 | $68.8M | — |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $37.1M | ||
| Q3 25 | $46.2M | $10.3M | ||
| Q2 25 | $208.5M | $-14.5M | ||
| Q1 25 | $236.3M | $28.3M | ||
| Q3 24 | $263.1M | — | ||
| Q2 24 | $113.0M | — | ||
| Q1 24 | $59.1M | — |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 7.3% | ||
| Q3 25 | 8.1% | 2.2% | ||
| Q2 25 | 37.5% | -4.6% | ||
| Q1 25 | 41.7% | 12.1% | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | — | ||
| Q1 24 | 13.9% | — |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 2.5% | ||
| Q3 25 | 0.5% | 1.8% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.7% | 1.9% | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 2.3% | — |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | 1.72× | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 1.84× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
TIC
| Consulting Engineering Segment | $300.1M | 59% |
| Geospatial Segment | $131.3M | 26% |
| Fixed Unit Price Contracts | $54.3M | 11% |
| Other | $22.6M | 4% |
